Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION

NCT00219557 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00219557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2005
Completion date
March 14, 2008
Enrollment
111 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms